AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22386043 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 5 ppm for up to 28 days
Number of subjects: 92
Study 22386043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 20436058 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 45
Study 20436058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18676075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/d
Number of subjects: 10060
Study 18676075 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10060
Study 18676075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 10060
Study 15807716 — intervention group
Group type: EXPERIMENTAL
Intervention: NFV 625 mg (1250 mg bid)
Number of subjects: 126
Study 15807716 — intervention group
Group type: EXPERIMENTAL
Intervention: NFV 625 mg
Number of subjects: 126
Study 15807716 — intervention group
Group type: COMPARATOR
Intervention: NFV 250 mg
Number of subjects: 126
Study 12364482 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF-14) 2.0 micro g/kg/h i.v. over 120 min
Number of subjects: 6
Study 12364482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortistatin (CST-14) 2.0 micro g/kg/h i.v. over 120 min
Number of subjects: 6
Study 12364482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10591454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal dental appliance for mandibular advancement
Number of subjects: 95
Study 10591454 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment, uvulopalatopharyngoplasty
Number of subjects: 95
Study 10591454 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnography with dental appliance
Number of subjects: 95
Study 10591454 — intervention group
Group type: COMPARATOR
Intervention: Somnography without dental appliance
Number of subjects: 95
Study 10591454 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events from dental appliance
Number of subjects: 95
Study 9156924 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)
Number of subjects: 75
Study 9156924 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (group IV)
Number of subjects: 75
Study 1931746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Remodent and 0.2% NaF solutions
Number of subjects: 123
Study 1931746 — intervention group
Group type: COMPARATOR
Intervention: 0.2% NaF solutions (Control group)
Number of subjects: 123
Study 7010881 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Number of subjects: 70
Study 7010881 — intervention group
Group type: COMPARATOR
Intervention: Mock stimulation
Number of subjects: 70
Study 31565869 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group (STD) - supervised exercise program (300 min/wk of moderate-intensity aerobic exercise) during months 0 to 6
Number of subjects: 170
Study 31565869 — intervention group
Group type: COMPARATOR
Intervention: Sequential group (SEQ) - refrained from exercise during months 0 to 6, then supervised exercise program during months 7 to 12
Number of subjects: 170
Study 31565869 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group (STD) - weight regain between 6 and 18 months
Number of subjects: 170
Study 31565869 — intervention group
Group type: COMPARATOR
Intervention: Sequential group (SEQ) - weight change between 6 and 18 months
Number of subjects: 170
Study 31565869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at 18 months
Number of subjects: 170
Study 30160222 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs (EGG)
Number of subjects: 0
Study 30160222 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg whites (WHITE)
Number of subjects: 0
Study 30160222 — intervention group
Group type: COMPARATOR
Intervention: Egg yolks (YOLK)
Number of subjects: 0
Study 30160222 — intervention group
Group type: COMPARATOR
Intervention: Glucose (GLU)
Number of subjects: 0
Study 26447687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SPT and pregabalin 300 mg daily
Number of subjects: 40
Study 26447687 — intervention group
Group type: COMPARATOR
Intervention: SPT alone
Number of subjects: 40
Study 24372921 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing with fluoride-containing dentifrice (1,100 ppm fluoride as sodium fluoride)
Number of subjects: 16
Study 24372921 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing with placebo dentifrice (0 ppm fluoride)
Number of subjects: 16
Study 22309472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure‐only therapy (Ex)
Number of subjects: 108
Study 22309472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure‐based treatment combined with cognitive restructuring (ExCR)
Number of subjects: 108
Study 19772765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mold-sensitive subjects (based on skin test reactivity)
Number of subjects: 34
Study 19772765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mold-sensitive subjects (SPT reactive subgroup)
Number of subjects: 34
Study 19772765 — intervention group
Group type: COMPARATOR
Intervention: Nonmold-sensitive subjects
Number of subjects: 34
Study 17705570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day for 6 weeks
Number of subjects: 200
Study 17705570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day
Number of subjects: 200
Study 17705570 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 40 mg/day
Number of subjects: 200
Study 17705570 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 20 mg/day + HCTZ 12.5 mg/day
Number of subjects: 200
Study 15479540 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who selected more attributes as important to their attitude
Number of subjects: 0
Study 15479540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambivalent attitudes
Number of subjects: 0
Study 15479540 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ambivalent attitudes
Number of subjects: 0
Study 15479540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambivalent attitude-holders
Number of subjects: 0
Study 11552924 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week regimen with ranitidine bismuth citrate 400 mg b.d. for 7 days
Number of subjects: 86
Study 11552924 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week regimen with ranitidine bismuth citrate 400 mg b.d. for 14 days
Number of subjects: 86
Study 11552924 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week regimen with ranitidine bismuth citrate 400 mg b.d. for 28 days
Number of subjects: 86
Study 9636857 — intervention group
Group type: EXPERIMENTAL
Intervention: BACI prior to C. parvum challenge (BACI group)
Number of subjects: 20
Study 9636857 — intervention group
Group type: EXPERIMENTAL
Intervention: BACI prior to and 30 minutes after challenge (reinforced BACI group)
Number of subjects: 20
Study 9636857 — intervention group
Group type: COMPARATOR
Intervention: Nonfat milk placebo prior to and 30 minutes after challenge
Number of subjects: 20
Study 7931747 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm condition (provision of intervention algorithm at each patient visit)
Number of subjects: 527
Study 7931747 — intervention group
Group type: COMPARATOR
Intervention: No-algorithm condition
Number of subjects: 527
Study 3144443 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg.kg‐1 nalbuphine intravenously
Number of subjects: 20
Study 3144443 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 3144443 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg.kg‐1 nalbuphine
Number of subjects: 20
Study 3144443 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg.kg‐1 nalbuphine
Number of subjects: 20
Study 29256032 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (SIM)
Number of subjects: 35
Study 29256032 — intervention group
Group type: COMPARATOR
Intervention: Didactic ECT curriculum (non‐SIM)
Number of subjects: 35
Study 27412799 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (3 g per day)
Number of subjects: 2
Study 27412799 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (340 mg per day)
Number of subjects: 2
Study 27412799 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (3% solution) and/or high-Mg diet (600 mg per 100 g)
Number of subjects: 2
Study 27412799 — intervention group
Group type: COMPARATOR
Intervention: Control group (WKY rats)
Number of subjects: 2
Study 24105406 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with Roux-en-Y gastric bypass (BPD-RYGBP)
Number of subjects: 130
Study 24105406 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 130
Study 22615543 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero tenofovir exposure
Number of subjects: 302
Study 22615543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ART in pregnancy
Number of subjects: 302
Study 22615543 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 302
Study 22615543 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ART regimens
Number of subjects: 302
Study 20691300 — intervention group
Group type: EXPERIMENTAL
Intervention: On-statin CETP mass
Number of subjects: 3218
Study 20691300 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP mass greater than the median
Number of subjects: 3218
Study 20691300 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP mass quartiles
Number of subjects: 3218
Study 18726564 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-fed group (2 eggs a day)
Number of subjects: 45
Study 18726564 — intervention group
Group type: COMPARATOR
Intervention: Non-egg-fed group
Number of subjects: 45
Study 16911650 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT questionnaire
Number of subjects: 80
Study 16911650 — intervention group
Group type: EXPERIMENTAL
Intervention: All questionnaires
Number of subjects: 80
Study 16911650 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Number of subjects: 80
Study 16911650 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of questionnaire
Number of subjects: 80
Study 14505263 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-Agonist induced reversible ovarian suppression
Number of subjects: 0
Study 14505263 — intervention group
Group type: COMPARATOR
Intervention: Progestins
Number of subjects: 0
Study 10539122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients followed by a general practitioner
Number of subjects: 294
Study 10539122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients followed by a neurologist
Number of subjects: 294
Study 10539122 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall costs
Number of subjects: 294
Study 10539122 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical indicators
Number of subjects: 294
Study 10539122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary care costs
Number of subjects: 294
Study 8834342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation at home for 12 weeks
Number of subjects: 43
Study 8834342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 43
Study 1677266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of alprazolam
Number of subjects: 8
Study 1677266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6362765 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine mesylate
Number of subjects: 28
Study 6362765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29904047 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated RES and BoNT
Number of subjects: 60
Study 29904047 — intervention group
Group type: COMPARATOR
Intervention: BoNT
Number of subjects: 60
Study 29904047 — intervention group
Group type: COMPARATOR
Intervention: RES
Number of subjects: 60
Study 29392283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelets in additive solution
Number of subjects: 790
Study 29392283 — intervention group
Group type: COMPARATOR
Intervention: Platelets in plasma
Number of subjects: 790
Study 29392283 — intervention group
Group type: COMPARATOR
Intervention: Platelets in additive solution
Number of subjects: 790
Study 29392283 — intervention group
Group type: COMPARATOR
Intervention: Pathogen-reduced platelets in additive solution vs platelets in plasma
Number of subjects: 790
Study 29392283 — intervention group
Group type: COMPARATOR
Intervention: Pathogen-reduced platelets in additive solution vs platelets in additive solution
Number of subjects: 790
Study 29392283 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 790
Study 26712560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 6 months
Number of subjects: 81
Study 26712560 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab monthly for 6 months
Number of subjects: 81
Study 26712560 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab PRN
Number of subjects: 81
Study 26712560 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab PRN plus laser
Number of subjects: 81
Study 24475026 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral rilapladib once daily for 14 days
Number of subjects: 84
Study 24475026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 22884658 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic dermoid cystectomy by mesial incision (33 patients)
Number of subjects: 67
Study 22884658 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic dermoid cystectomy by antimesial incision (34 patients)
Number of subjects: 67
Study 19284121 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg of ideal weight)
Number of subjects: 80
Study 19284121 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg of real weight)
Number of subjects: 80
Study 19284121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg of ideal weight)
Number of subjects: 80
Study 19284121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg of real weight)
Number of subjects: 80
Study 17873530 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0
Study 17873530 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (as preoperative adjuvant therapy)
Number of subjects: 0
Study 17873530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with albendazole and PAIR
Number of subjects: 0
Study 15692217 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron saccharate complex (ISC), 100 mg twice weekly for 2 months and once weekly thereafter
Number of subjects: 48
Study 15692217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC), 62.5 mg twice weekly for 2 months and once weekly thereafter
Number of subjects: 48
Study 12667322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pituitrin infusion (2 U/min) during gastroduodenal artery blockage
Number of subjects: 40
Study 12667322 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (10 ml at 4 ml/min) as control
Number of subjects: 40
Study 12667322 — intervention group
Group type: COMPARATOR
Intervention: Trial group vs Control group
Number of subjects: 40
Study 9707191 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL HS‐HES
Number of subjects: 9
Study 9707191 — intervention group
Group type: COMPARATOR
Intervention: 40 g mannitol
Number of subjects: 9
Study 7661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/g)
Number of subjects: 38
Study 7661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg/day)
Number of subjects: 38
Study 7661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pravastatin and Gemfibrozil (40 + 1200 mg/day)
Number of subjects: 38
Study 7661873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2756983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 24
Study 2756983 — intervention group
Group type: COMPARATOR
Intervention: No pyloroplasty (Control)
Number of subjects: 24
Study 601437 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 50
Study 601437 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 50
Study 31704740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 132
Study 31704740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily plus vitamin K2 2000 µg thrice weekly
Number of subjects: 132
Study 31704740 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs) with target INR 2‐3
Number of subjects: 132
Study 29485197 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT‐4‐BPSD
Number of subjects: 50
Study 29485197 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 50
Study 27722840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 618
Study 27722840 — intervention group
Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 618
Study 24509986 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Sprint Ability Training (RST)
Number of subjects: 16
Study 24509986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Training (IT)
Number of subjects: 16
Study 23812272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion of 2 mg/kgBW/h
Number of subjects: 36
Study 23812272 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (control group)
Number of subjects: 36
Study 20151997 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 0
Study 20151997 — intervention group
Group type: COMPARATOR
Intervention: Doubling atorvastatin to 80 mg
Number of subjects: 0
Study 18648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein (HPROT)
Number of subjects: 18
Study 18648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure tryptophan
Number of subjects: 18
Study 18648776 — intervention group
Group type: COMPARATOR
Intervention: Intact alpha-lactalbumin protein (ALAC)
Number of subjects: 18
Study 18648776 — intervention group
Group type: COMPARATOR
Intervention: Placebo protein
Number of subjects: 18
Study 18648776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-containing synthetic peptide
Number of subjects: 18
Study 16491133 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine plus 400 mg celecoxib for 6 weeks
Number of subjects: 40
Study 16491133 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine plus placebo for 6 weeks
Number of subjects: 40
Study 12881842 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training program (imagined wrist movements and mental simulations using a mirror box apparatus)
Number of subjects: 2
Study 11007240 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (OLT)
Number of subjects: 193
Study 11007240 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive drug therapy (glucocorticoids, cyclosporin, FK 506)
Number of subjects: 193
Study 8775364 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line skating in the 'sitting' position (LS)
Number of subjects: 7
Study 8775364 — intervention group
Group type: COMPARATOR
Intervention: In-line skating (US)
Number of subjects: 7
Study 8775364 — intervention group
Group type: COMPARATOR
Intervention: Running (TR)
Number of subjects: 7
Study 1523353 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg tid during 12 weeks
Number of subjects: 32
Study 1523353 — intervention group
Group type: COMPARATOR
Intervention: Placebo tid during 12 weeks
Number of subjects: 32
Study 6498567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: 0.65 MAC nitrous oxide (66% inspired) and 0.65 MAC isoflurane (0.75% end‐expired)
Number of subjects: 60
Study 6498567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 0.65 MAC nitrous oxide and 1‐1.2 MAC isoflurane (1.2‐1.4% end‐expired)
Number of subjects: 60
Study 6498567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: Same as Group I with addition of fentanyl (2 micrograms X kg‐1) before skin incision and 1/8 of the initial dose every 15 minutes during surgery
Number of subjects: 60
Study 6498567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV: Same as Group I with additional infusion of lidocaine (30 micrograms X kg‐1 X min‐1)
Number of subjects: 60
Study 6498567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V: 0.65 MAC of nitrous oxide and fentanyl (7.5 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Number of subjects: 60
Study 6498567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group VI: 0.65 MAC of nitrous oxide and fentanyl (15 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Number of subjects: 60
Study 31433108 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture
Number of subjects: 35
Study 31433108 — intervention group
Group type: COMPARATOR
Intervention: No Suture
Number of subjects: 35
Study 31433108 — intervention group
Group type: COMPARATOR
Intervention: Surgical Glue
Number of subjects: 35
Study 31433108 — intervention group
Group type: EXPERIMENTAL
Intervention: All Groups
Number of subjects: 35
Study 30541460 — intervention group
Group type: EXPERIMENTAL
Intervention: Activate intervention
Number of subjects: 14
Study 26251965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive memory strategy training (MST)
Number of subjects: 0
Study 26251965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive attention-perceptual-motor training (APM)
Number of subjects: 0
Study 26251965 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (PLA)
Number of subjects: 0
Study 26251965 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 0
Study 24331986 — intervention group
Group type: EXPERIMENTAL
Intervention: 1440-nm Nd:YAG laser irradiation with conventional root canal retreatment
Number of subjects: 40
Study 24331986 — intervention group
Group type: COMPARATOR
Intervention: Conventional root canal retreatment
Number of subjects: 40
Study 21940213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-pause method
Number of subjects: 14